stockrow
Friday 6 November 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
- EPS
- −34.5%
- Free cash flow
- −29.7%
Quarter to June 2026, against a year earlier
51.90
3.44
+7.10%
Follow MBX
Alert me
MBX Biosciences, Inc. (MBX) Operating margin
MBX Biosciences, Inc.'s operating margin over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | — |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Jun 2026 | 0.00% | 0.00 |
| Mar 2026 | 0.00% | 0.00 |
| Dec 2025 | 0.00% | 0.00 |
| Sep 2025 | 0.00% | 0.00 |
| 7 more quarters | Free account |
Operating margin against peers
| Company | Operating margin |
|---|---|
| ADMA ADMA Biologics Inc compare | 46.5% |
| MBX MBX Biosciences, Inc. | 0.00% |
| PHVS Pharvaris N.V. compare | 0.00% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −63.0% |
| XNCR Xencor, Inc. compare | −205.8% |
| RCUS Arcus Biosciences, Inc. compare | −475.0% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −725.4% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −900.1% |
| CLDX Celldex Therapeutics, Inc. compare | −36,733.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue